Petros Pharmaceuticals Future Growth
Future criteria checks 2/6
Petros Pharmaceuticals is forecast to grow earnings and revenue by 33.1% and 37.9% per annum respectively while EPS is expected to grow by 51% per annum.
Key information
33.1%
Earnings growth rate
51.0%
EPS growth rate
Pharmaceuticals earnings growth | 23.6% |
Revenue growth rate | 37.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Sep 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5 | -13 | N/A | N/A | 1 |
12/31/2025 | 5 | -13 | N/A | N/A | 1 |
12/31/2024 | 5 | -17 | N/A | N/A | 1 |
6/30/2024 | 4 | -21 | -9 | -9 | N/A |
3/31/2024 | 5 | -20 | -8 | -8 | N/A |
12/31/2023 | 6 | -14 | -8 | -8 | N/A |
9/30/2023 | 7 | -13 | -7 | -7 | N/A |
6/30/2023 | 4 | -22 | -5 | -5 | N/A |
3/31/2023 | 6 | -21 | -8 | -8 | N/A |
12/31/2022 | 6 | -20 | -13 | -13 | N/A |
9/30/2022 | 4 | -24 | -20 | -20 | N/A |
6/30/2022 | 8 | -12 | -19 | -19 | N/A |
3/31/2022 | 6 | -12 | -17 | -17 | N/A |
12/31/2021 | 8 | -9 | -12 | -12 | N/A |
9/30/2021 | 12 | -6 | -8 | -8 | N/A |
6/30/2021 | 13 | -8 | -10 | -10 | N/A |
3/31/2021 | 12 | -11 | -13 | -13 | N/A |
12/31/2020 | 10 | -21 | -15 | -15 | N/A |
9/30/2020 | 9 | -24 | -11 | -11 | N/A |
6/30/2020 | 10 | -29 | -9 | -9 | N/A |
3/31/2020 | 12 | -32 | -1 | -1 | N/A |
12/31/2019 | 16 | -33 | 2 | 3 | N/A |
12/31/2018 | 14 | -32 | 6 | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTPI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PTPI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PTPI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PTPI's revenue (37.9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: PTPI's revenue (37.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PTPI's Return on Equity is forecast to be high in 3 years time